Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
56
XLV Quote, Financials, Valuation and Earnings
Last price:
$153.94
Seasonality move
:
2.25%
Day range:
$153.37 - $155.03
52-week range:
$127.35 - $158.95
Dividend yield:
1.59%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
13.7M
Avg. volume:
14.6M
1-year change:
4.88%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XLV
State Street Health Care Select Sector SPDR ETF
|
$153.90 | -- | -- | -- | $0.62 | 1.59% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$212.83 | -- | -- | -- | $1.17 | 0.55% | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
$74.28 | -- | -- | -- | $0.26 | 1.38% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$82.06 | -- | -- | -- | $0.23 | 0.49% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$105.25 | -- | -- | -- | $0.24 | 0.95% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$123.25 | -- | -- | -- | $0.03 | 0.03% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | 0.326 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.657 | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | 0.458 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.316 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 1.273 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
State Street Health Care Select Sector SPDR ETF vs. Competitors
-
Which has Higher Returns XLV or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to State Street Health Care Select Sector SPDR ETF's net margin of --. State Street Health Care Select Sector SPDR ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XLVState Street Health Care Select Sector SPDR ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About XLV or FBT?
State Street Health Care Select Sector SPDR ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street Health Care Select Sector SPDR ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe State Street Health Care Select Sector SPDR ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings XLVState Street Health Care Select Sector SPDR ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is XLV or FBT More Risky?
State Street Health Care Select Sector SPDR ETF has a beta of 0.656, which suggesting that the stock is 34.433% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.562%.
-
Which is a Better Dividend Stock XLV or FBT?
State Street Health Care Select Sector SPDR ETF has a quarterly dividend of $0.62 per share corresponding to a yield of 1.59%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.55% to investors and pays a quarterly dividend of $1.17 per share. State Street Health Care Select Sector SPDR ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XLV or FBT?
State Street Health Care Select Sector SPDR ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. State Street Health Care Select Sector SPDR ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, State Street Health Care Select Sector SPDR ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street Health Care Select Sector SPDR ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XLVState Street Health Care Select Sector SPDR ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns XLV or FHLC?
Fidelity MSCI Health Care Index ETF has a net margin of -- compared to State Street Health Care Select Sector SPDR ETF's net margin of --. State Street Health Care Select Sector SPDR ETF's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XLVState Street Health Care Select Sector SPDR ETF-- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- -
What do Analysts Say About XLV or FHLC?
State Street Health Care Select Sector SPDR ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street Health Care Select Sector SPDR ETF has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe State Street Health Care Select Sector SPDR ETF is more attractive than Fidelity MSCI Health Care Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings XLVState Street Health Care Select Sector SPDR ETF0 0 0 FHLCFidelity MSCI Health Care Index ETF0 0 0 -
Is XLV or FHLC More Risky?
State Street Health Care Select Sector SPDR ETF has a beta of 0.656, which suggesting that the stock is 34.433% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.694, suggesting its less volatile than the S&P 500 by 30.622%.
-
Which is a Better Dividend Stock XLV or FHLC?
State Street Health Care Select Sector SPDR ETF has a quarterly dividend of $0.62 per share corresponding to a yield of 1.59%. Fidelity MSCI Health Care Index ETF offers a yield of 1.38% to investors and pays a quarterly dividend of $0.26 per share. State Street Health Care Select Sector SPDR ETF pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XLV or FHLC?
State Street Health Care Select Sector SPDR ETF quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. State Street Health Care Select Sector SPDR ETF's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, State Street Health Care Select Sector SPDR ETF's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street Health Care Select Sector SPDR ETF is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XLVState Street Health Care Select Sector SPDR ETF-- -- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- --
-
Which has Higher Returns XLV or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to State Street Health Care Select Sector SPDR ETF's net margin of --. State Street Health Care Select Sector SPDR ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XLVState Street Health Care Select Sector SPDR ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XLV or PBE?
State Street Health Care Select Sector SPDR ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street Health Care Select Sector SPDR ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe State Street Health Care Select Sector SPDR ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XLVState Street Health Care Select Sector SPDR ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XLV or PBE More Risky?
State Street Health Care Select Sector SPDR ETF has a beta of 0.656, which suggesting that the stock is 34.433% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.787%.
-
Which is a Better Dividend Stock XLV or PBE?
State Street Health Care Select Sector SPDR ETF has a quarterly dividend of $0.62 per share corresponding to a yield of 1.59%. Invesco Biotechnology & Genome ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.23 per share. State Street Health Care Select Sector SPDR ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XLV or PBE?
State Street Health Care Select Sector SPDR ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. State Street Health Care Select Sector SPDR ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, State Street Health Care Select Sector SPDR ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street Health Care Select Sector SPDR ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XLVState Street Health Care Select Sector SPDR ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XLV or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to State Street Health Care Select Sector SPDR ETF's net margin of --. State Street Health Care Select Sector SPDR ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XLVState Street Health Care Select Sector SPDR ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XLV or PJP?
State Street Health Care Select Sector SPDR ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street Health Care Select Sector SPDR ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe State Street Health Care Select Sector SPDR ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XLVState Street Health Care Select Sector SPDR ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XLV or PJP More Risky?
State Street Health Care Select Sector SPDR ETF has a beta of 0.656, which suggesting that the stock is 34.433% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.387%.
-
Which is a Better Dividend Stock XLV or PJP?
State Street Health Care Select Sector SPDR ETF has a quarterly dividend of $0.62 per share corresponding to a yield of 1.59%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.24 per share. State Street Health Care Select Sector SPDR ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XLV or PJP?
State Street Health Care Select Sector SPDR ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. State Street Health Care Select Sector SPDR ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, State Street Health Care Select Sector SPDR ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street Health Care Select Sector SPDR ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XLVState Street Health Care Select Sector SPDR ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XLV or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to State Street Health Care Select Sector SPDR ETF's net margin of --. State Street Health Care Select Sector SPDR ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XLVState Street Health Care Select Sector SPDR ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About XLV or XBI?
State Street Health Care Select Sector SPDR ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street Health Care Select Sector SPDR ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe State Street Health Care Select Sector SPDR ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings XLVState Street Health Care Select Sector SPDR ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is XLV or XBI More Risky?
State Street Health Care Select Sector SPDR ETF has a beta of 0.656, which suggesting that the stock is 34.433% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.918%.
-
Which is a Better Dividend Stock XLV or XBI?
State Street Health Care Select Sector SPDR ETF has a quarterly dividend of $0.62 per share corresponding to a yield of 1.59%. State Street SPDR S&P Biotech ETF offers a yield of 0.03% to investors and pays a quarterly dividend of $0.03 per share. State Street Health Care Select Sector SPDR ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XLV or XBI?
State Street Health Care Select Sector SPDR ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. State Street Health Care Select Sector SPDR ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, State Street Health Care Select Sector SPDR ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street Health Care Select Sector SPDR ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XLVState Street Health Care Select Sector SPDR ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
